56 results
8-K
EX-99.1
MBRX
Moleculin Biotech Inc
7 May 24
Moleculin Reports Higher AML Complete Remission (CR) Rates and Significant Durability with Additional Interim Subject Data
8:55am
of treatment to the point of disease relapse or death. At the end of January 2024, the Company completed recruiting the desired number of 2nd line subjects … death (suspected to be related to pneumonia) and one relapse to date out of the 9 CRcs. The first subject with a CRc (and who has yet to relapse
424B3
MBRX
Moleculin Biotech Inc
16 Feb 24
Prospectus supplement
5:19pm
, including death, as a result of their disease or due to other significant risks including relapse of their underlying malignancies. Many patients have … death. If a significant number of study subject deaths were to occur, regardless of whether such deaths are attributable to one of our drugs, our
8-K
EX-10.1
cq9u1j0 syyoyi
5 Jan 24
Departure of Directors or Certain Officers
5:14pm
8-K
EX-10.2
95fycl72t 0kam
5 Jan 24
Departure of Directors or Certain Officers
5:14pm
8-K
EX-10.3
9qhy090qe4qmo
5 Jan 24
Departure of Directors or Certain Officers
5:14pm
8-K
EX-3.1
b7bl73
21 Dec 23
Moleculin Announces Pricing of $4.5 Million Registered Direct Offering and Concurrent Private Placement Priced At-the-Market
5:17pm
8-K
EX-3.1
yf77sdqkvdw4z1 os
21 Aug 23
Amendments to Articles of Incorporation or Bylaws
5:17pm
S-8
EX-4.5
ok6sm6
21 Jun 23
Registration of securities for employees
5:16pm
S-8
EX-4.5
fbp4 ahp8tium14co77c
19 Jul 22
Registration of securities for employees
5:18pm